Tokyo, Japan
Tokyo, Japan

Repro India Ltd. is a provider of print, content and fulfillment solutions based in India. The company reported annual revenues of Rs 2554 million for the year ending in March 2011. Repro India is listed on the Bombay Stock Exchange and the National Stock Exchange of India. Wikipedia.


Time filter

Source Type

Patent
Repro | Date: 2015-03-28

A compact mechanical pump is provided. The pump is adjustable between a compact form and an expanded form, where the pump can be reduced to a compact form for ease of portability and storage and to the expanded form for use as a pump.


News Article | April 24, 2017
Site: marketersmedia.com

CHESTER, NY / ACCESSWIRE / April 24, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) ("RMS" or the "Company") announced today the United States Food and Drug Administration ("FDA") renewed the Company's Certificate to Foreign Government ("CFG"). A CFG is issued for legally marketed devices in the U.S. that are in compliance with the requirements of the Federal Food, Drug, and Cosmetic Act ("FFDCA"). A CFG is required by many market regulators in Asia, Europe, the Middle East and Latin America in order to legally sell medical devices in their territories. The renewal of this CFG confirms RMS devices have been cleared for sale in the U.S. and are in compliance with the requirements of the FFDCA. The CFG can be presented to regulators in foreign markets as part of the medical device registration process. Foreign governments often seek official assurance that products exported to their countries can be marketed in the U.S. and meet specific U.S. regulations, for example, current Good Manufacturing Practice ("cGMP") regulations and Quality System Regulations ("QSR"). "The FDA renewal of our CFG is confirmation of our product clearances and that RMS meets specific U.S. regulations including cGMPs and QSRs," said Eric Bauer, RMS Chief Operating Officer. "Our CFG allows RMS to continue our international expansion efforts and maintain our global leadership position. We are pleased the FDA recognizes the RMS Quality System meets U.S. regulations and that the FDA continues to support the sale of our products in the U.S., as well as other countries." RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes", "belief", "expects", "intends", "anticipates", "will", or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. For more information please call: CHESTER, NY / ACCESSWIRE / April 24, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) ("RMS" or the "Company") announced today the United States Food and Drug Administration ("FDA") renewed the Company's Certificate to Foreign Government ("CFG"). A CFG is issued for legally marketed devices in the U.S. that are in compliance with the requirements of the Federal Food, Drug, and Cosmetic Act ("FFDCA"). A CFG is required by many market regulators in Asia, Europe, the Middle East and Latin America in order to legally sell medical devices in their territories. The renewal of this CFG confirms RMS devices have been cleared for sale in the U.S. and are in compliance with the requirements of the FFDCA. The CFG can be presented to regulators in foreign markets as part of the medical device registration process. Foreign governments often seek official assurance that products exported to their countries can be marketed in the U.S. and meet specific U.S. regulations, for example, current Good Manufacturing Practice ("cGMP") regulations and Quality System Regulations ("QSR"). "The FDA renewal of our CFG is confirmation of our product clearances and that RMS meets specific U.S. regulations including cGMPs and QSRs," said Eric Bauer, RMS Chief Operating Officer. "Our CFG allows RMS to continue our international expansion efforts and maintain our global leadership position. We are pleased the FDA recognizes the RMS Quality System meets U.S. regulations and that the FDA continues to support the sale of our products in the U.S., as well as other countries." RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes", "belief", "expects", "intends", "anticipates", "will", or "plans" to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. For more information please call:


News Article | April 27, 2017
Site: www.accesswire.com

CHESTER, NY / ACCESSWIRE / April 27, 2017 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR) ("RMS" or the "Company"), announced that the Board of Directors approved a change in the Company's fiscal year end from February 28 to December 31. Accordingly, the Company will file its Form 10-K for the fiscal year ending February 28, 2017 in May 2017. For its new fiscal year ending December 31, 2017, it will file its Form 10-K for ten months ending December 31, 2017 and twelve months ending February 28, 2017 in March 2018. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March, 2017 and the quarter April through June 2017 on Form 10-Q in August 2017. "This change is being made by the Company to better align the Company's financial reporting calendar with its industry peers, suppliers and customers," said Karen Fisher, RMS Chief Financial Officer. "We recognize that the fiscal-year change will involve some short-term inconvenience for those who follow our financial results, but we believe it is the right thing to do for our business, and we're committed to providing the necessary information in a timely and transparent manner." RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief" "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. For more information, please call:


News Article | April 27, 2017
Site: marketersmedia.com

CHESTER, NY / ACCESSWIRE / April 27, 2017 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR) ("RMS" or the "Company"), announced that the Board of Directors approved a change in the Company's fiscal year end from February 28 to December 31. Accordingly, the Company will file its Form 10-K for the fiscal year ending February 28, 2017 in May 2017. For its new fiscal year ending December 31, 2017, it will file its Form 10-K for ten months ending December 31, 2017 and twelve months ending February 28, 2017 in March 2018. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March, 2017 and the quarter April through June 2017 on Form 10-Q in August 2017. "This change is being made by the Company to better align the Company's financial reporting calendar with its industry peers, suppliers and customers," said Karen Fisher, RMS Chief Financial Officer. "We recognize that the fiscal-year change will involve some short-term inconvenience for those who follow our financial results, but we believe it is the right thing to do for our business, and we're committed to providing the necessary information in a timely and transparent manner." RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief" "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. For more information, please call: CHESTER, NY / ACCESSWIRE / April 27, 2017 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR) ("RMS" or the "Company"), announced that the Board of Directors approved a change in the Company's fiscal year end from February 28 to December 31. Accordingly, the Company will file its Form 10-K for the fiscal year ending February 28, 2017 in May 2017. For its new fiscal year ending December 31, 2017, it will file its Form 10-K for ten months ending December 31, 2017 and twelve months ending February 28, 2017 in March 2018. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March, 2017 and the quarter April through June 2017 on Form 10-Q in August 2017. "This change is being made by the Company to better align the Company's financial reporting calendar with its industry peers, suppliers and customers," said Karen Fisher, RMS Chief Financial Officer. "We recognize that the fiscal-year change will involve some short-term inconvenience for those who follow our financial results, but we believe it is the right thing to do for our business, and we're committed to providing the necessary information in a timely and transparent manner." RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com. This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief" "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. For more information, please call:


The invention relates to methods of selecting needles with an injection length suited for administration of a therapeutic agent in the subcutis at a body location.


Provided is a precision variable flow rate infusion system and method for delivering a liquid from a reservoir having an initial potential outflow rate to a patient. The system includes at least a first flexible flow rate tubing having a pre-defined flow rate selected at a maximum dosage flow rate for the liquid from the reservoir, the pre-defined flow rate being less than the initial potential outflow rate of the reservoir. Also provided is an adjustable flow rate controller having an inlet and an outlet, at least one internal fluid pathway there between and a fluid pathway modifier structured and arranged to modify the internal fluid pathway from the inlet to the outlet from a closed pathway to a maximum flow pathway with a plurality of different flow rate pathways there between. Moreover, the at least first flexible flow rate tubing and adjustable flow rate controller determine the maximum flow rate of liquid from the reservoir to a patient and the adjustable flow rate controller permits precision flow rate control from an off flow rate to about the maximum flow rate permitted. Associated methods of providing, calibrating and using the precision variable flow rate infusion system are also provided.


Patent
Repro | Date: 2014-04-04

The present invention generally provides a device for inserting needles and alleviating the discomfort associated with needle insertion. In certain embodiments, the device is suited for injecting butterfly needles and particularly butterfly needles that are attached to infusion tubing. The patient or caregiver loads a butterfly needle with tubing attached into the base of the drive plunger. The needle with tubing attached is retracted into the housing of the device by retracting the inner plunger. Once retracted, the device is activated and ready to administer a needle into the tissue of a patient. The device is then placed on the location of the skin where injection is desired. The surface that contacts the skin may be textured and may include a contact switch that causes the device to vibrate when slight pressure is applied through contact with the skin. Two trigger buttons in the housing of the device may be depressed to eject the needle at an angle essentially perpendicular to the surface of the skin into the tissue of the patient concurrently with the textured pads contacting the skin and vibrating, distracting the patient from the needle insertion. The inner plunger of the device is then depressed toward the surface of the skin to release the needle from the device. The wings and body of the butterfly may be secured to the skin, for example, with an adhesive such as tape.


Patent
Repro | Date: 2015-02-20

The present disclosure relates to a connector for connecting flow channels, flow regulators and/or reservoirs for directing flow. In some embodiments, the connector is a medical connector for connecting fluid flow controlling elements used in medical applications, particularly in infusion systems, such as tubes, syringes, needles, catheters and fluid reservoirs. The connector reduces the risk of contamination during handling and enhances safety when administering therapeutic solutions into a patient.


A method for manufacturing of sleeves for anilox rolls, the sleeve comprising an inner sleeve (21) of compressible material and an outer sleeve (22) having an outer surface with ink transfer cells engraved therein. The method comprises the steps of providing an air mandrel (10), applying the inner sleeve (21) on the air mandrel (10), applying adhesive on the inner sleeve (21), applying the outer sleeve (22) on the inner sleeve (21), the outer sleeve being made of a black polymer having a hardness of between 85 and 90 Shore D (according to DIN53505), grinding the outer sleeve (22), laser-engraving ink transfer cells in the outer surface of the outer sleeve (22) with the user of a Near Infrared (NIR) laser, and polishing the outer surface of the outer sleeve (22).


Patent
Repro | Date: 2014-02-14

The invention provides a modular tubing system with a set of tubing segments that can be configured to provide a desired flow rate. In the modular systems described herein, multiple tubes with pre-set flow rates are attached either in-series or in parallel to allow the user to vary the flow rate of the therapy. The modular systems described herein may be used in connection with a constant pressure pump for subcutaneous administration of therapeutic agents.

Loading Repro collaborators
Loading Repro collaborators